<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740441</url>
  </required_header>
  <id_info>
    <org_study_id>AS1411-C-202</org_study_id>
    <nct_id>NCT00740441</nct_id>
  </id_info>
  <brief_title>A Phase II Study of AS1411 in Renal Cell Carcinoma</brief_title>
  <official_title>A Phase II, Open Label, Single Arm Study of AS1411 in Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antisoma Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antisoma Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal
      Cell Carcinoma
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the Overall Response Rate to AS1411</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure progression free survival with AS1411</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure time to disease progression with AS1411</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the duration of overall response and stable disease with AS1411</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and tolerability of two cycles of AS1411</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetic profile of AS1411</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess pharmacodynamic markers of AS1411</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AS1411 treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS1411</intervention_name>
    <description>AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed renal cell carcinoma containing predominant
             clear cell histology

          -  Failed or intolerant to 1 or more previous lines of treatments (which must include a
             Tyrosine Kinase Inhibitor)

        Exclusion Criteria:

          -  Collecting duct histology

          -  A history of bleeding disorders or currently taking oral vitamin K antagonise
             medication

          -  Unstable brain metastases

          -  History of prior or concomitant malignancy (except for curatively treated non-melanoma
             skin cancer or carcinoma in situ of the cervix, or other cancer for which the patient
             has been disease free for 3 years)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Francis Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry Drabkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Francis Hospital</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center, University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2008</study_first_submitted>
  <study_first_submitted_qc>August 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2008</study_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chris Smyth</name_title>
    <organization>Antisoma</organization>
  </responsible_party>
  <keyword>renal cell carcinoma</keyword>
  <keyword>rcc</keyword>
  <keyword>kidney cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

